Patozumab injection for the treatment of breast cancer has been approved for marketing!

Recently, the National Drug Administration approved the application for import registration of patuzumab injection, which was used in combination with trastuzumab and chemotherapy for adjuvant treatment of early breast cancer patients with high risk of recurrent human epidermal growth factor receptor 2 (HER2) positive The incidence rate of breast cancer is the highest in women After HER2 positive early breast cancer patients received Herceptin combined chemotherapy, about 1 / 4 of them still had disease recurrence or death 10-11 years later, and the proportion of high-risk early breast cancer patients had recurrence or death was higher Patuzumab injection is a new type of anti HER2 drug developed by Roche company It can produce anti HER2 effect by inhibiting the heterologous and homologous two polymers of HER2 The global key phase III adjuvant therapy research shows that compared with the current standard treatment of trastuzumab combined with chemotherapy, patazomab combined with trastuzumab and chemotherapy are used for the adjuvant treatment of HER2 positive early breast cancer patients with high risk of recurrence, significantly improving the patient's non-invasive disease survival period and controllable adverse reactions In view of the obvious clinical benefit / risk advantage of this product, on December 17, the National Drug Administration approved the import registration of this product, and combined with trastuzumab and chemotherapy for the adjuvant treatment of HER2 positive early breast cancer patients with high risk of recurrence In accordance with the relevant spirit of the CPC Central Committee and the State Council on deepening the reform of the drug review and approval system, the State Drug Administration encourages the simultaneous research and development, application and registration of innovative drugs at home and abroad For the clinical trial data obtained through the international multi center clinical trials, which meet the relevant requirements of drug registration, it is directly approved for listing, so that the patients in China can use the efficacy as soon as possible, with accurate and safe results Innovative drugs with controllable risks can better meet the needs of the public.